Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial.
Apr 2010 - :1477-2566 [PMID:20429791]
[Trepiakas R] [Berntsen A] [Hadrup SR] [Bjørn J] [Geertsen PF] [Straten PT] [Andersen MH] [Pedersen AE] [Soleimani A] [Lorentzen T] [Johansen JS] [Svane IM]

Mechanisms of murine dendritic cell antitumor dysfunction in aging.
Oct 2009 - Cancer Immunol. Immunother.; 58(12):1432-0851 [PMID:19082999]
[Grolleau-Julius A] [Abernathy L] [Harning E] [Yung RL]

Increases in serum TARC/CCL17 levels are associated with progression-free survival in advanced melanoma patients in response to dendritic cell-based immunotherapy.
Aug 2009 - J. Clin. Immunol.; 29(5):1573-2592 [PMID:19421847]
[Cornforth AN] [Lee GJ] [Fowler AW] [Carbonell DJ] [Dillman RO]

Genetically engineered Newcastle disease virus for malignant melanoma therapy.
Jun 2009 - Gene Ther.; 16(6):1476-5462 [PMID:19242529]
[Zamarin D] [Vigil A] [Kelly K] [García-Sastre A] [Fong Y]

Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
May 2009 - Prostate; 69(9):1097-0045 [PMID:19267351]
[Kim S] [Lee JB] [Lee GK] [Chang J]

Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.
May 2009 - Clin. Cancer Res.; 15(10):1078-0432 [PMID:19417017]
[Bonehill A] [Van Nuffel AM] [Corthals J] [Tuyaerts S] [Heirman C] [François V] [Colau D] [van der Bruggen P] [Neyns B] [Thielemans K]

Melanoma vaccines: The problems of local immunosuppression.
Apr 2009 - Hum. Immunol.; 70(5):1879-1166 [PMID:19405172]
[Polak ME] [Borthwick NJ] [Jager MJ] [Cree IA]

Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients.
Apr 2009 - Clin. Cancer Res.; 15(7):1078-0432 [PMID:19318472]
[Verdijk P] [Aarntzen EH] [Lesterhuis WJ] [Boullart AC] [Kok E] [van Rossum MM] [Strijk S] [Eijckeler F] [Bonenkamp JJ] [Jacobs JF] [Blokx W] [Vankrieken JH] [Joosten I] [Boerman OC] [Oyen WJ] [Adema G] [Punt CJ] [Figdor CG] [de Vries IJ]

The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells.
Apr 2009 - Exp. Dermatol.; 18(4):1600-0625 [PMID:19054057]
[Fujisawa Y] [Nabekura T] [Nakao T] [Nakamura Y] [Takahashi T] [Kawachi Y] [Otsuka F] [Onodera M]

Immunoregulatory T cells in the peripheral blood of melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
Mar 2009 - J. Dermatol. Sci.; 54(1):1873-569X [PMID:19157789]
[Nakai N] [Katoh N] [Kitagawa T] [Ueda E] [Takenaka H] [Kishimoto S]

Dendritic cells in the skin--potential use for melanoma treatment.
Jan 2009 - Pigment Cell Melanoma Res; 22(1):1755-1471 [PMID:19040502]
[El Marsafy S] [Bagot M] [Bensussan A] [Mauviel A]

TIMP-1-GPI in combination with hyperthermic treatment of melanoma increases sensitivity to FAS-mediated apoptosis.
Jan 2009 - Cancer Immunol. Immunother.; 58(3):1432-0851 [PMID:18618109]
[Djafarzadeh R] [Milani V] [Rieth N] [von Luettichau I] [Skrablin PS] [Hofstetter M] [Noessner E] [Nelson PJ]

Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
Dec 2008 - J. Dermatol. Sci.; 53(1):0923-1811 [PMID:18804963]
[Nakai N] [Katoh N] [Germeraad WT] [Kishida T] [Ueda E] [Takenaka H] [Mazda O] [Kishimoto S]

[Activation of anti-tumor cytotoxic T lymphocytes by fusion of human dendritic cells and melanoma cells]
Dec 2008 - Zhong Nan Da Xue Xue Bao Yi Xue Ban; 33(11):1672-7347 [PMID:19060369]
[Zhu HC] [Wu SH] [Huang BY] [Zhu B] [Gu HH] [Luo XB] [Xiong Z] [Chen WS]

Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells.
Nov 2008 - Cancer Res.; 68(22):1538-7445 [PMID:19010919]
[Minkis K] [Kavanagh DG] [Alter G] [Bogunovic D] [O'Neill D] [Adams S] [Pavlick A] [Walker BD] [Brockman MA] [Gandhi RT] [Bhardwaj N]